« Return to News | R&D Trends

Enanta, Novartis collaborate to advance Hep C inhibitor

Wednesday, February 22, 2012 01:53 PM

Enanta Pharmaceuticals, a developer of best-in-class small molecule drugs in the infectious disease field, has formed an exclusive collaboration and license agreement with Novartis for the worldwide development, manufacture and commercialization of its lead development candidate, EDP-239, a hepatitis C virus inhibitor.

Enanta will receive an upfront payment of $34 million and is eligible to receive up to $406 million in milestones and tiered, double-digit royalties on worldwide sales of products. It retains co-detail rights in the U.S. Novartis will be responsible for all costs associated with the development, manufacture and commercialization of EDP-239—which has received IND approval from the FDA—and will fund Enanta's drug discovery efforts on certain additional compounds targeting HCV.

"Novartis is a recognized leader in the field of HCV, and access to its global expertise combined with our shared vision for commercializing HCV therapies will support the successful development and commercialization of products," said Jay R. Luly, PhD, president and CEO, Enanta Pharmaceuticals.

He added, "We believe EDP-239 has great potential as a potent ingredient in combination drug therapy, and our preclinical studies have demonstrated high potency against multiple genotypes of the virus, excellent safety profile and a preclinical pharmacokinetic profile amenable to once-a-day dosing in humans."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.